Adding a personalized mRNA vaccine to standard immunotherapy lowered the risk of melanoma returning or causing death by 42% in a large Phase 3 trial. Merck and Moderna released the detailed results from the INTerpath-001 trial ahead of a presentation on Saturday, Oct. 24, at the European Society for Medical Oncology (ESMO) Congress in Madrid. The trial involved adults whose high-risk melanoma had already been removed by surgery.
The most important question still has no answer. Overall survival, the measure that shows whether a treatment helps patients live longer, has not been fully reported because those data are not yet mature. That gap will shape how doctors, regulators, and insurers view the vaccine.
